ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
ProMIS is developing antibodies selectively targeting misfolded forms of TDP-43 and SOD1.
- ProMIS is developing antibodies selectively targeting misfolded forms of TDP-43 and SOD1.
- ALS is a fatal neurodegenerative disease of motor neurons.
- “Publication of these data underscores the connection of misfolded proteins and ALS and supports targeting our TDP-43-specific epitope with PMN267 as a potential therapeutic approach,” stated Neil Warma, Chief Executive Officer of ProMIS Neurosciences.
- “PMN267 is advancing through preclinical development and is showing promise as a potential treatment for ALS.